ATE412745T1 - Antiangiogene peptide vom n-terminus von endostatin - Google Patents

Antiangiogene peptide vom n-terminus von endostatin

Info

Publication number
ATE412745T1
ATE412745T1 AT04782583T AT04782583T ATE412745T1 AT E412745 T1 ATE412745 T1 AT E412745T1 AT 04782583 T AT04782583 T AT 04782583T AT 04782583 T AT04782583 T AT 04782583T AT E412745 T1 ATE412745 T1 AT E412745T1
Authority
AT
Austria
Prior art keywords
endostatin
terminus
peptides
antiangiogenic peptides
nucleic acids
Prior art date
Application number
AT04782583T
Other languages
English (en)
Inventor
Judah Folkman
Kashi Javaherian
Robert Sjin
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE412745T1 publication Critical patent/ATE412745T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
AT04782583T 2003-08-29 2004-08-30 Antiangiogene peptide vom n-terminus von endostatin ATE412745T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49926403P 2003-08-29 2003-08-29
US53921304P 2004-01-26 2004-01-26

Publications (1)

Publication Number Publication Date
ATE412745T1 true ATE412745T1 (de) 2008-11-15

Family

ID=34278655

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04782583T ATE412745T1 (de) 2003-08-29 2004-08-30 Antiangiogene peptide vom n-terminus von endostatin
AT04816838T ATE401400T1 (de) 2003-08-29 2004-08-30 Antiangiogene peptide zur behandlung oder vorbeugung von endometriose

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04816838T ATE401400T1 (de) 2003-08-29 2004-08-30 Antiangiogene peptide zur behandlung oder vorbeugung von endometriose

Country Status (10)

Country Link
US (1) US7645735B2 (de)
EP (2) EP1668129B1 (de)
JP (2) JP2007525972A (de)
KR (1) KR20070030159A (de)
AT (2) ATE412745T1 (de)
AU (2) AU2004285847A1 (de)
CA (2) CA2537179A1 (de)
DE (2) DE602004015142D1 (de)
IL (1) IL173952A0 (de)
WO (2) WO2005021756A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525972A (ja) 2003-08-29 2007-09-13 チルドレンズ メディカル センター コーポレーション エンドスタチンのｎ末端からの抗血管新生性ペプチド
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN100398557C (zh) * 2006-04-05 2008-07-02 中国药科大学 血管生成抑制多肽及其制备方法和应用
CN100427503C (zh) * 2006-09-08 2008-10-22 哈尔滨医科大学 内皮抑制素小分子多肽及编码该多肽的核苷酸序列和互补链
JP2010504359A (ja) 2006-09-20 2010-02-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 局部麻酔および／または疼痛緩和のための、揮発性麻酔剤を送達するための方法
CA2712731C (en) 2008-01-22 2016-05-03 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US8507441B2 (en) * 2009-10-22 2013-08-13 University of Pittsburgh—Of the Commonwealth Systems of Higher Education Use of endostatin peptides for the treatment of fibrosis
US9944862B2 (en) 2013-11-18 2018-04-17 Indian Oil Corporation Limited Process and a system for enhancing liquid yield of heavy hydrocarbon feedstock
WO2015071773A1 (en) 2013-11-18 2015-05-21 Indian Oil Corporation Limited A catalyst for enhancing liquid yield in thermal coking process
CN115433268B (zh) * 2015-07-27 2025-10-03 上海贺普药业股份有限公司 一种肿瘤抑制肽
RU2711085C1 (ru) * 2019-08-12 2020-01-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Полипептид для ингибирования миграции и инвазии рака предстательной железы
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
CN113845582B (zh) * 2021-10-15 2022-05-27 南京市妇幼保健院 内源性多肽在制备预防或治疗子宫内膜癌靶向药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
EP0857210B1 (de) * 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutische antiangiogenische zusammensetzungen und verfahren
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
WO1998005293A2 (en) 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
DE69824750T2 (de) * 1997-10-31 2005-07-07 Children's Medical Center Corp., Boston Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
WO1999029856A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Restin and methods of use thereof
US6653098B1 (en) 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
AU3199999A (en) * 1998-03-24 1999-10-18 Children's Medical Center Corporation Endostatin derived peptides with anti-angiogenic and anti-cancer activity
CA2331370A1 (en) * 1998-06-03 1999-12-09 The Children's Medical Center Corporation Protein oligomer compositions comprising endostatin protein and methods of using the same
JP2002523036A (ja) * 1998-08-25 2002-07-30 レキシジェン ファーマシューティカルズ コーポレイション イムノフュージンとしての新脈管形成インヒビターの発現および輸送
US7317003B2 (en) * 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
AU4342000A (en) * 1999-04-13 2000-11-14 Merck & Co., Inc. Soluble recombinant endostatin and method of making same from (streptomyces sp)
IT1312077B1 (it) 1999-04-15 2002-04-04 Univ Degli Studi Milano Polipeptidi ad attivita' antiangiogenica.
AU4982200A (en) * 1999-05-06 2000-11-21 Burnham Institute, The Antiangiogenic endostatin peptides, endostatin variants and methods of use
US20020086007A1 (en) * 2000-10-13 2002-07-04 Sim Kim Lee Angiogenesis-inhibiting peptides and proteins and methods of use
ITMI20010394A1 (it) 2001-02-27 2002-08-27 Univ Degli Studi Milano Peptidi ad attivita' antiangiogenica
US20060122374A1 (en) * 2002-02-07 2006-06-08 Peter Mertins Albumin-fused anti-angiogenesis peptides
JP2007525972A (ja) 2003-08-29 2007-09-13 チルドレンズ メディカル センター コーポレーション エンドスタチンのｎ末端からの抗血管新生性ペプチド
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin

Also Published As

Publication number Publication date
WO2005021756A1 (en) 2005-03-10
EP1687426A2 (de) 2006-08-09
ATE401400T1 (de) 2008-08-15
EP1687426B1 (de) 2008-07-16
US7645735B2 (en) 2010-01-12
AU2004269399A1 (en) 2005-03-10
WO2005042566A3 (en) 2005-10-06
EP1668129A1 (de) 2006-06-14
KR20070030159A (ko) 2007-03-15
DE602004015142D1 (de) 2008-08-28
EP1668129B1 (de) 2008-10-29
IL173952A0 (en) 2006-07-05
CA2537236A1 (en) 2005-05-12
WO2005042566A2 (en) 2005-05-12
CA2537179A1 (en) 2005-03-10
JP2007529410A (ja) 2007-10-25
US20060258583A1 (en) 2006-11-16
JP2007525972A (ja) 2007-09-13
AU2004285847A1 (en) 2005-05-12
DE602004017487D1 (de) 2008-12-11

Similar Documents

Publication Publication Date Title
DE602004017487D1 (de) Antiangiogene peptide vom n-terminus von endostatin
CY1117351T1 (el) Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης
ATE400656T1 (de) Mini-dystrophin nukleinsäure- und peptidsequenzen
MX9606536A (es) Proteinas n-terminalmente extendidas expresadas en levaduras.
YU71800A (sh) Hibridni polipeptidi sa pojačanim farmakokinetičkim osobinama
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
DE60030450D1 (de) Von MUC-1 abgeleitete Peptide
DE60138558D1 (de) Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
ATE533845T1 (de) Eukaryotische signalsequenzen zur polypeptid- expression und polypeptid-anzeigebibliotheken
DE60221051D1 (de) Herstellung von peptiden und proteinen durch anhäufung in vom endoplasmatischen reticulum abgeleiteten proteinkörpern
ATE417618T1 (de) Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
ATE477269T1 (de) Tolerogene peptide des basischen myelinproteins
WO2005035570A3 (en) Variants of cd40l protein
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE477272T1 (de) Verwendung von stefin a als gerüstprotein
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
ATE448793T1 (de) Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
ATE503834T1 (de) Bibliotheken rekombinanter chimärischer proteine
WO2003059281A3 (en) Novel variants of rankl protein
ATE466876T1 (de) Immunogene konstrukte
FI20031050A0 (fi) Mentelmä proteiinien katkaisuun
DE60008749D1 (de) Therapeutische peptide aus untersequenzen von bpi
ATE400288T1 (de) Peptide mit hohem cysteingehalt
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties